Similar to two other hematopoietic growth factor receptors, the c-fms (macrophage colony-stimulating factor receptor) and the c-kit genes, c-mpl has been discovered through the study of oncogenic retroviruses. Unlike c-fms and c-kif, which both belong to a subgroup of tyrosine kinase receptors, the c-mpl proto-oncogene encodes a new member of the cytokine receptor superfamily. We have studied the expression of c-mpl in a series of 105 patients with hematologic malignancies using Northern blot analysis. The levels of c-mpl transcripts in lymphoid malignancies and in chronic myeloproliferative disorders were not significantly different from those found in normal bone marrow cells, in which c-mpl was barely detectable. In HE PROLIFERATION and maturation of hematopoi-
T etic cells are tightly regulated by factors that positively or negatively modulate pluripotential stem cell proliferation and multilineage differentiation. These effects are mediated through the high-affinity binding of extracellular factors to specific cell surface receptors. Human leukemic cells have been shown to express functional receptors for a variety of hematopoietic growth factors including interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) granulocyte-CSF (G-CSF), macrophage-CSF (M-CSF), and stem cell factor.'-7 Several investigators have shown that deregulated expression of growth factors and/or growth factor receptors could be involved in the pathogenesis of human leukemias and myeloproliferative syndromes. [8] [9] [10] [11] [12] We have recently cloned complete cDNAs of a new member of the cytokine receptor superfamily designed as c-mpl.I3 This family includes not only cytokine receptors such as the IL-2 receptor 0 and y chains and the receptors for IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, GM-CSF, G-CSF, erythropoietin, LIF, and oncostatin M, but also the growth hormone and prolactin receptors.'416 c-mpl is the cellular homologue of the viral oncogene transduced in an acute defective murine retrovirus, the myeloproliferative leukemia virus (MPLV).I7 Within a few weeks, mice infected with MPLV develop an hepatosplenomegaly and their hematopoietic progenitors yield terminally differentiating cells in vitro in the absence of any added growth f a c t~r . '~* '~ Infection of bone marrow cells in vitro with MPLV generates autonomous growth factor-independent hematopoietic cell lines belonging to various lineages." Previously, we showed that expression of the c-mpl proto-oncogene was restricted to nonlymphoid hematopoietic tissues." Therefore, it seemed to be of interest to study the expression of this gene in patients suffering from different hematopoietic malignancies. Very low or undetectable levels of c-mpl transcripts were found in cells from patients with lymphoid malignancies or with myeloproliferative and myelodysplastic syndromes in chronic phase. However, c-mpl expression was markedly detectable in 26 of 5 1 cases of acute myeloblastic leukemia (AML). In one case of AML, high expression was associated with a genomic amplification of the lp34 region encompassing the c-mpl locus.2o c-mpl expression was frequently observed in patients with secondary AML developed during the progression of myeloprolifera- tive or myelodysplastic syndromes and in AML patients with poor prognosis because of chemotherapy-resistant disease, including most AML patient's with deletions of chromosomes 5 and/or 7.
Although c-mpl expression was detected only in malignancies with immature blast cell proliferation, its expression did not uniformly correlate with the presence of immature blast cells. Our results suggest that c-mpl expression in AML patients could be of prognostic significance in predicting response to induction therapy.
MATERIALS AND METHODS
Patients and cell line. Peripheral blood (PB) or bone marrow (BM) samples were obtained from 105 patients (104 adults and 1 child) who had been referred to the Hematology Department at the Hapita1 Cochin between 1988 and 1992. All specimens were collected before the initiation of therapy and were obtained from 5 1 patients with AML, 11 with acute lymphoblastic leukemia (ALL), 19 with myeloproliferative disorders (MPD) in chronic phase, 8 with non-Hodgkin's lymphoma (NHL), and 16 with myelodysplastic syndromes (MDS) ( Table 1 ). The diagnosis of each AML was established on the basis of morphologic and cytochemical staining, and patients were classified according to the criteria of the FrenchAmerican-British (FAB) committee.*' Two patients were classified asFAB MO, 2 as MI, 13 asM2, 5 Table 2 ) and 1 patient with apoor performance status (UPN 51). One patient (UPN 49) refused therapy. Complete remission (CR) after induction chemotherapy was defined by a normocellular marrow with less than 5% blasts. We considered induction failure patients as those with resistant disease and those who died of infection or bleeding during induction therapy. Patients with resistant AML and with a good performance status received a second course of chemotherapy with mitoxantrone at 12 mg/m2/d for 3 days, etoposide at 200 mg/mz/d on days 8 through 10, and cytosine arabinoside at 500 mg/m2/d on days 1 through 3 and 8 through 10." mRNA preparation and Northern blot analysis. PB or BM cells were isolated after Ficoll-Hypaque density gradient centrifugation and washed three times in Hanks' balanced salt solution. RNA was extracted by the guanidium thiocyanate procedure.23 After precipitation in ethanol at -2O"C, RNA pellets were resuspended in water. RNA concentrations were determined by optical density, and samples were frozen at -80°C until use.
RNA samples ( 10 pg of total RNA) were denatured in glyoxal, dimethyl sulfoxide, and phosphate buffer at 65°C for 10 minutes, size-fractionated by electrophoresis through 1 % agarose gel, and transferred to nylon membrane. Membranes were hybridized with random '2P-labeled probes and washed under stringent conditions as previously described." The c-mpl probe used in this study was a 280-bp-long fragment located in the human c-mpl extracellular domain. given by Dr G. Uzan (U 2 I7-Grenoble, Grenoble, France).
DNA preparation and Southern blot analysis. High molecular weight DNA was extracted by conventional methods. DNAs (10 pg) were digested with restriction enzymes under reaction conditions recommended by the manufacturers. Agarose gel electrophoresis, Southern blot transfer, and hybridization were performed as previously described.17 Probes used as markers of the 1p32-34 chromosomal region were tal-1, L-myc, c-jun (provided by Dr D. MathieuMahul, U 301, Pans, France), lck (provided by Dr R. Benarous, U 332, Paris, France), Rhesus (from Dr J.P. Cartron, CNTS, Pans, France), and a G-CSF receptor probe (given by Dr S. Gillis, Immunex, Seattle, WA).
Cytogenetic analyses. The cytogenetic study was performed on 37 patients with AML at diagnosis on BM samples. Cells were cultured for 24 or 48 hours before chromosome preparation. When possible, 20 metaphases were photographed and analyzed after reverse heat G (RHG) banding of the chromosomes?5 Karyotypes were described according to the International System for Human Cytogenetic Nomenclature.26
Statistical analysis. The x2 test was used to determine significance of qualitative variable differences. Probabilities of c.05 were considered statistically significant. The log-rank test was used to compare the groups of patients with respect to achieving CR and disease-free survival.27 RESULTS c-mpl is expressed in patients with AML or RAEB.
RNAs isolated from PB or BM from 105 patients with hematologic malignancies described in Materials and Methods and Table 1 were studied for c-mpl expression by Northern blot analysis. We previously reported that c-mpl was detected as a major 3.7-kb and a minor 2.7-kb mRNA species in the human HEL cell line. Both transcripts have been cloned, and they potentially code for polypeptides that share common extracellular and transmembrane domains but differ in their cytoplasmic regions. These two mRNA probably derive from a unique c-mpl gene by alternative ~plicing.'~ To study c-mpl expression, we used as a probe a fragment located in the mpl extracellular domain that detects the two c-mpl transcripts in HEL cells (Fig I , lane a) .
As shown in Fig 1, no signal was detected in mRNA isolated from normal PB cells (Fig 1, lane b) , and c-mpl was barely detectable as a faint 3.7-kb transcript in BM samples from healthy individuals (Fig 1, lane c) . Very low c-mpl expression was detected in the 19 patients with lymphoproliferative disorders and in the 19 patients with MPD in chronic phase. In contrast, c-mpl mRNA levels appeared to be elevated in 26 of 5 1 ( 5 1 %) AML patients and in 5 of 16 (31%) MDS patients. Typical results are shown in Fig 1. Variability in intensity was seen among patients despite equal loading (as verified by 6-actin hybridization), but cmpl expression in patient samples was usually lower than in HEL cells, except for 1 patient (UPN 23 in Table 2 ) who presented with a diagnosis of AML, subtype M4 (Fig 1, lane  g ). Although the 3.7-kb c-mpl transcript was consistently expressed more than the 2.7-kb c-mpl mRNA species, as observed in normal BM and in HEL cells (in BM, the level of mpl expression is not high enough to detect the 2.7-kb transcript), the 2.7-kb c-mpl transcript was found to be quite abundant in the two cases shown in Fig 1, lanes g and i. In AML patients, it appeared that blast cell populations were heterogeneous with respect to the expression of c-mpl. were found in patients with M2, M3, M4, M5, and M6 AML (Table I) . However, it is noticeable that, although the percentage of blast cells were lower in M6 AML samples than in other AML subtypes, all patients with M6 leukemias were c-mpl positive.
No significant correlation was found between c-mpl expression and the FAB classification because c-mpl transcripts
Of the 16 MDS patients, none of the 5 patients with RSA had increased c-mplexpression, whereas 5 ofthe I I patients with a diagnosis of RAEB showed increased c-mpl transcripts (Table I) .
The c-mpl gene is amplified in one patient with an M4 AML. To determine whether genomic alterations might be responsible for high expression, genomic DNAs of leukemic cells from patients expressing the highest levels of c-mpl mRNA were subjected to Southern blot analysis. No gross alteration of the c-mplgene was detected in these DNA samples, except in DNA from UPN 23, in which a c-mpl gene amplification was found (Fig 2A, lanes a and d) . Although cytogenetic analysis was not available for this patient, these Correlation between c-mpl expression andclinicaland bioIogicSeatirres in AML. The characteristics of the AML population we studied are listed in Table 2 . We found no significant correlation between c-mpl expression and characteristics such as sex, age, white blood cells, and platelets counts or the origin of sampling (PB or BM) (TaLes 2 and 3). The HEL cell line which has megakaryocytic and erythroid characteristics is the only human hematopoietic cell line we tested in which we detected c-mpl transcripts by Northern blot analy~is.'~ Consequently, we investigated the possibility of a correlation between GPIIb, glycophorin, and c-mpl expression in AML. By immunophenotyping, only M6 AML expressed the early erythroid glycophorin marker. Northern blots from AML patients were rehybridized with a GPIIb probe. No correlation was found between GPIlb and c-mpl expression (data not shown).
Of the 51 AML cases we studied, 16 were presumably secondary leukemias; 12 were blast crises arising during the progression of either chronic MDS (UPN 7, 14, 15, 30 , 50, and 5 1) or MPD (UPN 8, 12 , 17,24, 28, and 35); I patient (UPN 49) had been professionally exposed to irradiation; and 3 patients (UPN 3,25, and 32) had received chemotherapy after diagnosis of a solid tumor. Sixty-eight percent ( 1 1 of 16) of these 16 secondary leukemias were c-mpl positive versus 43% (1 5 of 35) of the 35 AML patients presenting with a diagnosis of de novo AML (Table 3) .
Prognostic value of e-mpl expression in AML. Thirty seven patients with AML could be classified into prognostic groups based on the results of cytogenetic studies according to the prognostic cytogenetic criteria of Keating et a129 and In contrast, among the 19 c-mpl-positive AML, only 6 had good prognostic characteristics: 3 had no cytogenetic abnormalities, 2 had a translocation t( 15,17)(q22q 1 l), and 1 had a t(8,2 l)(q22q22). However, 13 patients had chromosomal abnormalities affecting chromosome 5 and/or 7 or chromosome deletions or additions. As summarized in Table 3 , 70% (14 of 20) of AML with a good prognostic karyotype were c-mpl negative, whereas 76% (1 3 of 17) of AML with a high-risk karyotype were classified as c-mpl positive. The correlation between high c-mpl expression and the presence of a poor prognosis karyotype was highly significant (P < .001).
Of 5 c-mpl-negative AML who did not achieve CR. Of the 13 c-mpl-positive patients who failed to enter CR, 5 patients with a good performance status were treated with a second course of chemotherapy, as indicated in Materials and Methods. None of these 5 patients reached CR. However, in our experience, this intensive therapy leads to CR in 45% of refractory AML, suggesting a primary resistance in c-mplpositive AML.22 Because too few patients in the c-mpl-positive group achieved CR, a meaningful comparison of the duration of remission could not be performed.
DISCUSSION
In this report, the expression of the c-mpl gene that encodes a new member of the cytokine receptor superfamily was examined by Northern blot analysis in cells from patients with various hematologic neoplasms. RNA blot analysis show that c-mpl transcripts were not detectable in normal PB and were expressed at very low levels in normal BM cells. We found c-mpl mRNA to be expressed above normal BM cell levels in 5 1 % of AML and in 5 of 1 1 RAEB samples. No increase in expression was observed in acute leukemias of lymphoid origin, in lymphoma cells, or in samples of myelodysplastic or myeloproliferative disorders in chronic phase. This result contrasts with the biologic properties of MPLV, a murine retrovirus that has transduced a constitutively activated form of this receptor chain and induces the overproliferation of differentiating hematopoietic progenitors. Therefore, it seems very unlikely that c-mpl expression in AML is responsible for the impaired differentiation of AML blasts; but, because c-mpl is a component of a growth factor signal transduction pathway, expression of the c-mpl product could play a role in the proliferation of these cells. c-mpl expression in AML may be caused by an alteration of the c-mpl gene or may reflect the expansion of a cell population that normally expresses the c-mpl gene and represents only a small proportion of normal BM cells.
Amplification of the c-mpl gene evidenced in AML DNA was probably responsible for high c-mpl expression in 1 M4 AML (UPN 23). Two AML had translocations involving the lp36 region, but 1 (UPN 38) did not express c-mpl. However, UPN 32 expressed a normal-sized c-mp13.7-kb transcript at relatively low levels (not shown). No gross alteration or amplification of the c-mpl gene was detected in the DNA of other c-mpl-positive AML.
c-mpl expression in AML was associated with poor prognosis because, compared with c-mpl-negative AML, the cmpl-positive AML had a significantly lower rate of CR in response to chemotherapy. Chemotherapy resistance disease was the main cause of induction failure in c-mpl-positive AML. Therefore, we wondered whether c-mpl expression would correlate with other factors known to be of prognostic significance in AML. c-mpl expression did not significantly correlate with age, leucocyte count, or platelet count. Characteristics of the 26 patients with c-mpl-positive AML and of the 25 patients with c-mpl-negative AML were compared and showed that c-mpl was more frequently expressed in secondary than in de novo AML. Moreover, our results showed that c-mpl expression correlated with the presence of cytogenetic abnormalities known to be of major prognostic value in the outcome of AML in terms of both CR rate and long-term disease-free s u r~i v a l .~~~~" We noted that 1 1 of the 12 AML patients with abnormalities leading to loss of the whole chromosome or part of chromosome 5 and/or chromosome 7 were c-mpl positive. AML with deletion of chromosomes 5 and/or 7 represent a subset of AML characterized by poor prognosis usually because of chemotherapy-resistant disease.
Although c-mpl did not correlate with the FAB classification, the fact that 5 erythroleukemias (FAB M6) were all Interestingly, our study on MDS patients shows that, similar to AML, elevated c-mpl expression could also be associated with a poor prognosis. Indeed, 5 of 1 1 RAEB patients had increased c-mpl expression versus none of the 5 RSA patients. A survey of c-mpl expression in a larger panel of MDS patients is currently being performed in an attempt to define the precise relationship between c-mpl expression and the emergence of a blastic cell population.
Further studies on the c-mpl protein will show whether c-mpl is a ligand binding chain or a part of a multimeric complex. Because c-mpl has the overall structure of cytokine receptor, one could suppose that expression of the cmpl gene product may promote the proliferation of myeloid blast cells in vivo.
